Truvada/Sustiva combo fails in second attempt

A second attempt to combine Truvada and Sustiva into a single HIV pill has failed, says Gilead Sciences. The failure will delay an application to the FDA until sometime next year, said Gilead, which saw its shares slide on the news this morning. A spokesperson for Gilead said that researchers plan to employ new technology in mixing the drugs in the next round. Gilead earns about $1.33 billion a year from the sale of HIV drugs.

- read this story from the Los Angeles Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.